Inflammation  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

132 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT00088504: Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

Completed
2b
315
US
Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
Vertex Pharmaceuticals Incorporated
Hepatitis C, Hepatitis
 
10/06
PILLAR, NCT00882908 / 2008-007147-13: A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

Checkmark PILLAR and ASPIRE
Aug 2014 - Aug 2014: PILLAR and ASPIRE
Checkmark PILLAR & ASPIRE
Jun 2014 - Jun 2014: PILLAR & ASPIRE
Checkmark PILLAR
More
Completed
2b
386
US, Canada, Europe, RoW
TMC435, TMC 435, Ribavirin (R), COPEGUS, PegIFNα-2a (P), PEGASYS, Placebo
Tibotec Pharmaceuticals, Ireland
Hepatitis C
04/10
04/11
ASPIRE, NCT00980330 / 2009-010590-20: A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

Checkmark PILLAR and ASPIRE
Aug 2014 - Aug 2014: PILLAR and ASPIRE
Checkmark PILLAR & ASPIRE
Jun 2014 - Jun 2014: PILLAR & ASPIRE
Checkmark ASPIRE
More
Completed
2b
463
US, Canada, Europe, RoW
TMC435, Placebo, Peg-IFN-alfa-2a (P), PEGASYS, Ribavirin (R), COPEGUS
Tibotec Pharmaceuticals, Ireland
Hepatitis C
08/11
08/11
HEPCAT, NCT01125189 / 2010-018295-24: Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

Checkmark COMMAND-1
Aug 2014 - Aug 2014: COMMAND-1
Checkmark EASL 2013: COMMAND 1
Apr 2013 - Apr 2013: EASL 2013: COMMAND 1
Checkmark AASLD 2012: COMMAND-1
More
Completed
2b
558
US, Canada, Europe, RoW
Daclatasvir, Placebo, peg-interferon alfa-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
04/12
08/12
NCT01257204 / 2010-022408-28: Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Checkmark
Oct 2014 - Oct 2014: 
Checkmark AGW 2013: COMMAND GT2/3
Sep 2013 - Sep 2013: AGW 2013: COMMAND GT2/3
Checkmark EASL 2013: COMMAND GT2/3
More
Completed
2b
196
US, Canada, Europe, RoW
Placebo, Daclatasvir, BMS-790052, Pegylated interferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
05/12
09/12
HEPCAT, NCT01170962 / 2010-019378-34: Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

Completed
2b
512
US, Canada, Europe, RoW
BMS-790052, Placebo, peginterferon alfa-2a, Pegasys®, ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
06/12
12/12
NCT01271790 / 2010-023952-10: A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed
2b
245
US, Europe
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Gilead Sciences
Hepatitis C, Chronic
01/13
09/13
NCT01225380 / 2010-020911-35: A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2b
324
US, Canada, Europe
GS-9190, GS-9256, Pegasys®, Copegus®, GS-9190 placebo, GS-9256 placebo
Gilead Sciences
Chronic Hepatitis C Infection
01/13
09/13
NCT01516918 / 2011-004150-26: A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Completed
2b
103
US, Canada, Europe
VX-222, telaprevir, Incivek, VX-950, Incivo, ribavirin, Copegus, peginterferon-alfa-2a, Pegasys
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus
09/13
12/13
NCT01706575 / 2012-000080-25: A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression

Completed
2b
76
Europe
Pegylated Interferon (Peginterferon) Alfa-2a, Pegasys, Nucleos(t)ide Analogues (NA)
Hoffmann-La Roche
Hepatitis B, Chronic
09/13
11/14
D-LITE, NCT01795911: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Completed
2b
165
US
Pegylated Interferon Lambda, BMS-914143, Ribasphere, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
04/14
09/14
D-LITE, NCT01309932 / 2010-022568-11: Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE - APASL 2013
Jun 2013 - Jun 2013: D-LITE - APASL 2013
Checkmark D-LITE
More
Completed
2b
165
Japan, US, Europe, RoW
Pegylated Interferon Lambda (pegIFNλ), BMS-914143, BMS-790052 (NS5A Inhibitor), BMS-790052, Ribavirin (RBV), Ribasphere, BMS-650032 (NS3 Protease Inhibitor), BMS-650032, Pegylated Interferon Alfa-2a (pegIFNα-2a), Pegasys®, Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo for BMS-650032, Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for BMS-790052, Placebo for Ribavirin (RBV), Placebo for Ribasphere
Bristol-Myers Squibb
Hepatitis C
07/14
09/14
PADD-ON, NCT01524679: Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-Antigen

Completed
2b
170
Europe
Pegylated interferon alfa-2a plus nucleos(t)ide(s), Pegasys®
Johannes Gutenberg University Mainz, Roche Pharma AG
Chronic Hepatitis B
08/17
08/17
NCT01030432 / 2009-013652-69: Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin

Checkmark
Jul 2014 - Jul 2014: 
Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark
More
Completed
2a/2b
285
US, Europe, RoW
BMS-650032, Placebo, Pegasys, Peginterferon Alfa-2a, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
10/12
10/12
EMERGE, NCT01001754 / 2009-011786-80: Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Checkmark EMERGE
Jul 2014 - Jul 2014: EMERGE
Checkmark Data-EASL
Apr 2012 - Apr 2012: Data-EASL
Checkmark Data-AASLD
More
Unknown status
2a/b
600
Europe, Canada, US, RoW
PEG-rIL-29, Peginterferon alfa-2a, PEGASYS, Ribavirin
ZymoGenetics, Bristol-Myers Squibb
Hepatitis C, Chronic
11/10
05/12
NCT00528528 / 2007-001044-44: An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Completed
2a
166
Europe
Telaprevir, Peg-IFN-alfa-2a, Peg-IFN-alfa-2b, Ribavirin (RBV) tablet, Ribavirin (RBV) capsule
Tibotec BVBA
Chronic Hepatitis C
07/09
08/09
NCT00874770 / 2009-010149-29: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

Checkmark Data-AASLD
Oct 2011 - Oct 2011: Data-AASLD
Checkmark Data
Mar 2011 - Mar 2011: Data
Completed
2a
74
US, Europe
Daclatasvir, Placebo, Peginterferon alpha-2a, Pegasys, ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Infection
11/09
01/11
NCT01142700: A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I

Withdrawn
2a
0
US
BMS-824393, Placebo, Peginterferon Alpha-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Chronic Hepatitis C Virus Genotype 1
12/10
12/10
HEPCAT, NCT01193361: Ph IIA Study (SOC +/- NS5B)

Checkmark EASL 2012
Apr 2012 - Apr 2012: EASL 2012
Completed
2a
39
US
BMS-791325, Placebo, Peg-interferon alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C Virus
06/11
11/12
NCT01017575: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

Checkmark
Jan 2014 - Jan 2014: 
Checkmark
Jan 2014 - Jan 2014: 
Completed
2a
55
Japan
Daclatasvir, Placebo, Peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Infection
10/11
10/11
NCT01265511: Study of SCY-635, Pegasys and Copegus in Hepatitis C

Completed
2a
10
US
Placebo, Batch # BMR/10/731, SCY-635, Pegasys, Copegus
Scynexis, Inc.
Hepatitis C Infection
10/11
10/11
NCT00983853 / 2008-007995-81: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

Checkmark Data
May 2013 - May 2013: Data
Checkmark P2 data
Mar 2012 - Mar 2012: P2 data
Checkmark Data
More
Completed
2a
62
US, Europe
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited
Hepatitis C, HIV Infections
03/12
 
ROCO2, NCT00221650: Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients

Completed
2
17
Europe
Peginterferon alfa2a, Ribavirin
University Hospital, Bordeaux, Hoffmann-La Roche, Ministry of Health, France
HIV Infections, Hepatitis C, Chronic, Treatment Failure
 
06/04
NCT00262483: Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Completed
2
12
US
VX-950, ribavirin, peginterferon alfa-2a
Vertex Pharmaceuticals Incorporated
Hepatitis C
 
04/06
NCT00196586: Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

Completed
2
75
Europe
Interleukin 2, pegylated interferon alpha 2a, ribavirin
French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche
HIV Infections, Chronic Hepatitis C
 
11/06
NCT00433069: Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Completed
2
5
Europe
Pioglitazone, Actos, Interferon Alfa-2a, Pegasys, Ribavirin, Copegus
University Hospital, Geneva
Chronic Hepatitis C
12/07
01/08
NCT00336479: Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Completed
2
263
US
Telaprevir, VX-950, Ribavirin, RBV, Pegylated Interferon Alfa 2a, Peg-IFN-alfa-2a, Placebo
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
02/08
02/08
2006-006803-35: An open-label, randomized, multicenter, active-controlled,dose-ranging study to evaluate the safety and efficacy ofalbinterferon alfa-2b administered every 4 weeks plusribavirin in interferon alfa-naïve patients with genotype 1chronic hepatitis C

Terminated
2
600
Europe
albinterferon alfa-2b, Ribavirin, ABF656A, Solution for injection, Capsule, soft, Concentrate for solution for injection, PEGASYS
NOVARTIS FARMA
CHONIC HEPATITIS C
 
 
NCT00372385 / 2006-000828-14: Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Completed
2
334
Europe
Ribavirin, Pegylated Interferon Alfa 2a, Placebo, Telaprevir, VX-950
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
05/08
06/08
NCT00377182: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Completed
2
107
US
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Hoffmann-La Roche
Hepatitis C, Chronic
08/08
08/08
NCT00763568: 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis C

Completed
2
40
RoW
Nitazoxanide, Alinia, Peginterferon alfa-2a, PEGASYS
Romark Laboratories L.C.
Chronic Hepatitis C
09/08
09/08
PIFNPK, NCT00085917: Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Completed
2
29
US
Double dose pegylated interferon with weight based Ribavirin, Pegasys, standard dose pegylated interferon alfa -2a and ribavirin, pegasys
National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, HIV Infections
11/08
11/08
NCT00420784 / 2006-004665-33: A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Checkmark EASL 2013: PROVE3
Apr 2013 - Apr 2013: EASL 2013: PROVE3
Completed
2
465
US, Canada, Europe
Telaprevir, VX-950, Ribavirin, RBV, Pegylated Interferon Alfa 2a, Peg-IFN-alfa-2a, Matching Placebo
Vertex Pharmaceuticals Incorporated
Hepatitis C
12/08
04/09
NCT00561353 / 2007-003289-16: A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

Completed
2
121
Europe
TMC435, Placebo, Peginterferon (PegIFNα-2a), PEGASYS, Ribavirin, COPEGUS
Tibotec Pharmaceuticals, Ireland
Hepatitis C, Chronic
12/08
05/10
NCT02731131: A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)

Completed
2
12
Europe
Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis D, Chronic
05/09
05/09
NCT00517439 / 2006-006604-11: A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Checkmark P2 data
Dec 2011 - Dec 2011: P2 data
Completed
2
516
US, Canada, Europe, RoW
Copegus, Pegasys, RO4588161
Hoffmann-La Roche
Hepatitis C, Chronic
01/10
01/10
STEALTHC-2, NCT00495391: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C

Completed
2
64
US
Nitazoxanide, Alinia, Placebo, Peginterferon alfa-2a, PEGASYS, Ribavirin, COPEGUS
Romark Laboratories L.C.
Chronic Hepatitis C
02/10
02/10
NCT00535847 / 2006-005123-42: A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Completed
2
117
US, Canada, Europe
Telaprevir, VX-950, Ribavirin, Pegylated interferon alfa 2a
Vertex Pharmaceuticals Incorporated, Tibotec, Inc
Hepatitis C
02/10
02/10
NCT00720434: A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Completed
2
35
US
PF-00868554, Placebo
Pfizer
Hepatitis C
03/10
03/10
NCT02716779 / 2006-000935-86: Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

Completed
2
68
Europe
Pegylated Interferon (PEG-IFN) alfa-2a, Pegasys®, Placebo, Ribavirin, Copegus®
Hoffmann-La Roche, Roche Pharma AG
Hepatitis C, Chronic
04/10
04/10
NCT00537407: A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Completed
2
50
US
Debio 025, Alisporivir, Peg-IFNα2a, PEGASYS, Ribavirin, Copegus
Debiopharm International SA
Chronic Hepatitis C
04/10
04/10
STEALTHC-3, NCT00637923: Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients

Completed
2
112
US
Nitazoxanide, Alinia, Placebo, Peginterferon alfa-2a, PEGASYS, Ribavirin, COPEGUS
Romark Laboratories L.C.
Chronic Hepatitis C
04/10
04/10
NCT01054729: Dose-Ranging Study of Sofosbuvir in Combination With Pegylated Interferon and Ribavirin in Treatment Naïve GT 1 HCV Patients

Completed
2
64
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, Placebo, PEG, Pegasys®, RBV, Copegus®
Gilead Sciences
Hepatitis C
04/10
08/11
NCT01011166: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Completed
2
81
US
IDX184, Placebo, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV)
Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
07/10
07/10
NCT00854802 / 2008-004605-34: A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Checkmark AASLD 2011
Oct 2011 - Oct 2011: AASLD 2011
Checkmark EASL 2011
Mar 2011 - Mar 2011: EASL 2011
Completed
2
290
Europe
Debio 025, Alisporivir, Peg-IFNα2a, Pegasys, Ribavirin, Copegus, Rebetol, Ribasphere, Vilona, Virazole, Debio 025 placebo
Debiopharm International SA, Parexel
Chronic Hepatitis C
09/10
09/10
NCT01072695 / 2009-013690-18: Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

Checkmark EASL 2012
Mar 2011 - Mar 2011: EASL 2012
Completed
2
46
Europe
GS-9256, GS-9190, Ribavirin, COPEGUS, Peginterferon alfa-2a, Pegasys
Gilead Sciences
HCV Infection
10/10
01/12
NCT00814606: A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C

Withdrawn
2
0
US
Fluvastatin, Peginterferon alfa2a, Pegasys, ribavirin, Copegus
University of Chicago
Hepatitis C, Hepatitis C Virus
10/10
10/10
NCT00991289: Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Completed
2
68
US
Nitazoxanide (NTZ), Alinia, Pegylated interferon alfa-2a (PEG), Pegasys, Ribavirin (RBV), Copegus
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Hepatitis C Infection
11/10
01/12
2010-021963-34: A Phase 2, Randomized, Double-Blind, Comparator-Controlled, 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who were Nonresponders to Pegylated-Interferon plus Ribavirin

Terminated
2
100
Europe, RoW
IMO-2125, IMO-2125, Powder for solution for injection, Tablet, Solution for injection, Copegus, Pegasys 180µg
Idera Pharmaceuticals, Inc.
This is a Phase 2, randomized, double-blind, comparator-controlled study of IMO-2125 in hepatitis C-infected patients who were previously nonresponders to standard treatment (pegylated-interferon plus ribavirin) – that is, were treated at least 12 weeks and never achieved an undetectable viral load during or at the end of treatment.The population under study is nonresponder patients with chronic hepatitis C virus (HCV) infection.
 
 
PEGIFN, NCT01140997: Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C

Completed
2
211
RoW
Ypeginterferon alfa-2b, Peginterferon alfa-2b, Peginterferon alfa-2a, Pegasys
Xiamen Amoytop Biotech Co., Ltd., Peking University People's Hospital
Chronic Hepatitis C
01/11
03/12
NCT00944684: High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Completed
2
32
Europe
High ribavirin dose, Standard ribavirin dose
University of Bern, Roche Pharma AG, University of Lausanne, Cantonal Hospital of St. Gallen, Waid City Hospital, Zurich, University of Basel
Chronic Hepatitis C
04/11
04/11
NCT01143662: Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Completed
2
205
RoW
Ypeginterferon alfa-2b, Peginterferon alfa-2a, Pegasys
Xiamen Amoytop Biotech Co., Ltd., Peking University First Hospital
Chronic Hepatitis B
04/11
04/12
NCT01188772: Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients

Checkmark Sofosbuvir + PEG-2a + R (G 1, 2 & 3)
Mar 2013 - Mar 2013: Sofosbuvir + PEG-2a + R (G 1, 2 & 3)
Checkmark Data-AASLD
Oct 2011 - Oct 2011: Data-AASLD
Checkmark SVR-12 data
More
Completed
2
147
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, Placebo to match sofosbuvir, PEG, Pegasys®, RBV, Copegus®
Gilead Sciences
Hepatitis C Virus
04/11
05/12
NCT01273064: Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Terminated
2
114
US
CTS-1027, pegylated interferon, Pegasys, Ribavirin, Copegus, Placebo
Conatus Pharmaceuticals Inc.
Hepatitis C
09/11
10/11
CTS-1027-04, NCT01051921: Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Completed
2
67
US
CTS-1027, Pegylated interferon, Pegasys, Ribavirin, Copegus
Conatus Pharmaceuticals Inc.
Hepatitis C
11/11
12/11
NCT01439373: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Completed
2
16
US
GSK2336805, Pegylated interferon alfa-2a, Pegasys, Ribavirin, GSK2336805 Matching Placebo, Placebo
GlaxoSmithKline, PPD
Hepatitis C, Chronic
12/11
12/11
NCT00963885 / 2009-009608-38: A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Checkmark
Jul 2013 - Jul 2013: 
Checkmark AASLD 2011: ATLAS
Oct 2011 - Oct 2011: AASLD 2011: ATLAS
Completed
2
229
US, Canada, Europe, RoW
Copegus, Pegasys, Placebo, RO5190591 (Danoprevir)
Hoffmann-La Roche
Hepatitis C, Chronic
01/12
01/12
NCT01273948: Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

Completed
2
66
RoW
Bavituximab, Bavituxmab, Pegylated interferon (PEG-IFN), Pegasys
Peregrine Pharmaceuticals
Hepatitis C
01/12
02/12
NCT00869661 / 2008-008258-21: A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Checkmark PROPEL & JUMP-C
Mar 2014 - Mar 2014: PROPEL & JUMP-C
Checkmark EASL data
Apr 2012 - Apr 2012: EASL data
Completed
2
413
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048
Hoffmann-La Roche
Hepatitis C, Chronic
02/12
02/12
NCT00704405 / 2008-000150-12: Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Checkmark EASL 2014
Mar 2014 - Mar 2014: EASL 2014
Checkmark
Oct 2013 - Oct 2013: 
Checkmark APASL 2013
More
Completed
2
285
NA
Vaniprevir, MK-7009, Pegylated Interferon (Peg-IFN), PEGASYS™, Ribavirin (RBV), COPEGUS™, Placebo (PBO)
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
03/12
09/12
NCT01057667: A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Checkmark PROPEL & JUMP-C
Mar 2014 - Mar 2014: PROPEL & JUMP-C
Checkmark Data-EASL
Apr 2012 - Apr 2012: Data-EASL
Completed
2
168
US, Canada
RO5024048, Ribavirin [Copegus], peginterferon alfa-2a [Pegasys]
Hoffmann-La Roche
Hepatitis C, Chronic
04/12
04/12
SOFIA-LTT , NCT00442572: Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Completed
2
21
Europe
PEGASYS [peginterferon alfa-2a]
Hoffmann-La Roche
Hepatitis B, Chronic
04/12
04/12
ETOC, NCT00901524 / 2008-000859-10: ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIV

Checkmark EASL 2013: ANRS-HC-20 ETOC
Apr 2013 - Apr 2013: EASL 2013: ANRS-HC-20 ETOC
Checkmark P2 AASLD (peginterferon 2a+2b)
Oct 2012 - Oct 2012: P2 AASLD (peginterferon 2a+2b)
Completed
2
58
Europe
Peg-interféron alpha 2a + ribavirin
ANRS, Emerging Infectious Diseases, Roche Pharma AG
Hepatitis
06/12
06/12
NCT01329978: Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

Checkmark Sofosbuvir+pegylated interferon alfa-2a+ribavirin(ATOMIC)
Mar 2013 - Mar 2013:  Sofosbuvir+pegylated interferon alfa-2a+ribavirin(ATOMIC)
Checkmark ATOMIC
Oct 2012 - Oct 2012: ATOMIC
Completed
2
332
US
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV, Copegus®, PEG, Pegasys®
Gilead Sciences
Hepatitis C, Chronic
08/12
08/12
NCT01012895: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark APASL 2014
Mar 2014 - Mar 2014: APASL 2014
Checkmark In patients previously failed SOC
More
Completed
2
215
US, Europe
BMS-790052, BMS-650032, Pegylated-interferon alfa-2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Chronic Hepatitis C
10/12
02/14
INFORM-SVR, NCT01278134 / 2010-022067-35: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1

Checkmark
May 2014 - May 2014: 
Checkmark EASL 2012: INFORM-SVR
Apr 2012 - Apr 2012: EASL 2012: INFORM-SVR
Completed
2
170
US, Europe, RoW
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
10/12
10/12
NCT00606086 / 2007-005385-12: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Completed
2
140
US
GI-5005, Pegasys and Ribavirin, Pegylated Interferon and Ribavirin
GlobeImmune
Genotype 1 Chronic Hepatitis C
11/12
11/12
NCT00892697: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)

Completed
2
15
US
Telaprevir, Peginterferon alfa-2a, Ribavirin
Weill Medical College of Cornell University, Vertex Pharmaceuticals Incorporated
Hepatitis C
12/12
12/12
NCT01220947 / 2010-019584-10: A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Checkmark AASLD 2012: DAUPHINE
Oct 2012 - Oct 2012: AASLD 2012: DAUPHINE
Completed
2
421
US, Canada, Europe, RoW
Copegus, Danoprevir, Pegasys, Ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
12/12
12/12
NCT01331850 / 2010-019585-90: A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Checkmark MATTERHORN
Sep 2014 - Sep 2014: MATTERHORN
Checkmark AASLD 2012: MATTERHORN
Oct 2012 - Oct 2012: AASLD 2012: MATTERHORN
Completed
2
381
US, Canada, Europe, RoW
Copegus, Pegasys, RO5024048, danoprevir, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
01/13
01/13
NCT01371604 / 2011-001878-25: Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Checkmark IDX-184+/-(P+R)
Jun 2012 - Jun 2012: IDX-184+/-(P+R)
Completed
2
68
US
IDX184, Peginterferon alfa-2a (Peg-IFN), Pegasys, Ribavirin (RBV), Placebo
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
03/13
10/14
NCT01903954: A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

Completed
2
283
US
peginterferon alfa-2a [Pegasys], placebo, ribavirin [Copegus], setrobuvir, ANA598
Hoffmann-La Roche
Hepatitis C, Chronic
05/13
05/13
NCT00943761 / 2009-013053-15: A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Completed
2
45
NA
Vaniprevir 600 mg b.i.d., Vaniprevir 300 mg b.i.d., Pegylated interferon, PEGASYS™, Ribavirin, COPEGUS™
Merck Sharp & Dohme LLC
Hepatitis C, Chronic
05/13
05/13
NCT01289496: Ribavirin Dose Optimization for the Treatment of Hepatitis C

Completed
2
13
Canada
Peg-interferon alpha-2a, Ribavirin, Peg-interféron alpha-2a (PEGASYS), Ribavirin (COPEGUS)
Centre hospitalier de l'Université de Montréal (CHUM), Hoffmann-La Roche, Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Chronic Hepatitis C
08/13
08/13
NCT01425970: Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Terminated
2
210
US
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir, BMS-790052
Bristol-Myers Squibb
Hepatitis C
08/13
08/13
NCT01908335: A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Completed
2
212
RoW
PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis C
08/13
07/14
TelapreVIH, NCT01332955: Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Checkmark ANRS HC26 TelapreVIH
Aug 2014 - Aug 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
Mar 2014 - Mar 2014: CROI 2014: ANRS HC26 TelapreVIH
Checkmark CROI 2014: ANRS HC26 TelapreVIH
More
Completed
2
70
Europe
Telaprevir, VX-950, pegIFN alfa-2a, peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, Rebetol®
ANRS, Emerging Infectious Diseases, Janssen-Cilag Ltd.
Hepatitis C, Chronic, HIV Infection
09/13
09/13
NCT01483742 / 2011-004129-28: A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Completed
2
43
US, Canada, Europe, RoW
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
09/13
09/13
NCT01080222: A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Checkmark ZENITH
Jun 2014 - Jun 2014: ZENITH
Checkmark ZENITH - APASL 2013
Jun 2013 - Jun 2013: ZENITH - APASL 2013
Checkmark AASLD 2012
More
Terminated
2
152
US, RoW
telaprevir, VX-222, ribavirin, peginterferon-alfa-2a
Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C Virus Infection
10/13
11/13
NCT01260350: Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Checkmark EASL 2014: ELECTRON
Mar 2014 - Mar 2014: EASL 2014: ELECTRON
Checkmark APASL 2014: ELECTRON
Mar 2014 - Mar 2014: APASL 2014: ELECTRON
Checkmark HepDART 2013: LONESTAR & ELECTRON
More
Completed
2
292
RoW
SOF, Sovaldi®, GS-7977, PSI-7977, RBV, Copegus®, PEG, Pegasys®, LDV, GS-5885, GS-9669, LDV/SOF, Harvoni®
Gilead Sciences
Chronic Hepatitis C Infection
10/13
12/13
LIRA-B, NCT01204762 / 2010-020387-38: Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

Completed
2
197
US, Canada, Europe, RoW
pegIFN, pegIFNα-2a, Pegasys, PegIFN lambda, BMS-914143, Entecavir, Baraclude
Bristol-Myers Squibb
Hepatitis B Virus
12/13
12/13
NCT01482403 / 2011-002714-37: A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Completed
2
58
US, Canada, Europe
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Hoffmann-La Roche
Hepatitis C, Chronic
01/14
01/14
NCT01482390 / 2011-002715-28: A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Completed
2
80
US, Canada, Europe
Ribavirin, Copegus, Mericitabine, Peginterferon Alfa-2a, Pegasys, Placebo, Telaprevir
Hoffmann-La Roche
Hepatitis C
01/14
01/14
NCT01579019: A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn
2
0
US
RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Hoffmann-La Roche
Hepatitis C, Chronic
03/14
03/14
NCT01467505: An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Terminated
2
61
US, Canada
Telaprevir, VX-950, Ribavirin, Copegus®, RBV, Pegylated Interferon Alfa-2a, Pegasys®, Peg-IFN-alfa-2a, Immunosuppressant Regimen
Vertex Pharmaceuticals Incorporated
Hepatitis C
04/14
04/14
NCT01648140: Dose Ranging of GSK2336805 in Combination Therapy

Completed
2
286
US, Europe
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Pegasys, Ribavirin, Ribasphere, Telaprevir, Incivek (United States), Incivo (European Union)
GlaxoSmithKline, PPD
Hepatitis C, Chronic
07/14
07/14
NCT01153919: Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

Terminated
2
27
US
romiplostim, AMG 531, Amgen megakaryopoiesis protein 2, Nplate, ribavirin, ICN-1229, Rebetol, RIBA, RTCA, Viramide, Virazole, placebo, PLCB, PEG-interferon alfa-2a, PEG-IFNA2a, PEGASYS, pegylated interferon alfa-2a, laboratory biomarker analysis
University of Southern California
Hepatitis C Infection, Thrombocytopenia
07/14
07/18
NCT01428063 / 2011-000836-27: Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials

Completed
2
276
US, Canada, Europe, RoW
Daclatasvir, BMS-790052, Asunaprevir, BMS-650032, Pegylated interferon alfa-2a, pegIFNα-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus Infection
09/14
12/14
2014-003894-41: Effect of Interferon on protecting immune response in chronic hepatitis B patients under treatment for the infection with standard antiviral therapy Effetto dell’Interferone sulla risposta immunitaria proteggente in pazienti con epatite B cronica già in trattamento per l’infezione con terapia antivirale standard

Ongoing
2
80
Europe
Peginterferone alfa-2a, Entecavir, Tenofovir Disoproxil, Solution for injection in pre-filled syringe, Tablet, Pegasys, Baraclude, Viread
Azienda Ospedaliero-Universitaria di Parma, F. Hoffmann - La Roche Ltd, Gilead Sciences srl, Regione Emilia-Romagna
Chronic hepatitis B infection Infezione da Epatite B cronica, Chronic hepatitis B infection Infezione da Epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
NCT01749150: A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis

Completed
2
61
RoW
danoprevir + ritonavir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
Hoffmann-La Roche
Hepatitis C, Chronic
02/15
02/15
NCT02216045: Effect of Camel Milk on Chronic Hepatitis C

Completed
2
40
RoW
Peginterferon, Ribavirin, camel milk, PEGASYS® COPEGUS®. Dromedary milk (camel milk ), Peginterferon, Ribavirin, PEGASYS® (Peginterferon ) , COPEGUS® (Ribavirin)
Mashhad University of Medical Sciences
Chronic Hepatitis C
02/15
02/15
NCT01826981: Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed
2
359
RoW
LDV/SOF, Harvoni®, GS-5885/GS-7977, SOF, GS-7977, Sovaldi®, RBV, Peg-IFN, Pegasys®, GS-9669, VEL, GS-5816
Gilead Sciences
Chronic Hepatitis C
03/15
05/15
2014-000815-15: add-on therapy of HBV chronic infection Terapia di associazione sequenziale della epatite B cronica

Ongoing
2
40
Europe
pegylated interferon alpha 2a, Suspension for injection in pre-filled pen, Pegasys
Azienda Ospedaliera, Polo Universitario Luigi Sacco, Milano, Università degli Studi di Milano
Chronic hepatitis B Epatite B cronica, Chronic Hepatitis B epatite B cronica, Diseases [C] - Virus Diseases [C02]
 
 
LOWR-1, NCT02430181: Lonafarnib With and Without Ritonavir in HDV

Completed
2
21
RoW
lonafarnib, Sarasar, EBP994, peginterferon alfa-2a, Pegasys, pegylated interferon-alfa, PEG IFN-alfa, PEG IFN-a, ritonavir, Norvir, RTV
Eiger BioPharmaceuticals
Chronic Hepatitis D Infection
09/15
11/15
2006-002695-17: A multi-centre, randomised, double-blind, placebo-controlled escalating dose ranging phase II study on the efficacy of DEBIO-025 to reduce HCV viral load in combination with PEGASYS 180 g/week in treatment na ve patients with chronic hepatitis C and on the safety of this combination therapy

Completed
2
30
Europe
DEBIO-025, PEGASYS*SC SIR 0,5ML 180MCG+AG, PEGASYS*SC SIR 0,5ML 180MCG+AG
DEBIOPHARM S.A.
treatment na ve patients with chronic hepatitis C
 
 
2006-005500-14: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION)

Completed
2
80
Europe
Tretinoin, peginterferon alfa-2a, Ribavirin, Ro 01-5488, Ro 25-8310, Ro 20-9963, Vesanoid, Pegasys, Copegus, Vesanoid, Pegasys, Copegus
Universitätsmedizin der Johannes-Gutenberg Universität Mainz
chronic HCV infection
 
02/11
2009-011099-31: A Multi-center, Randomized, Double-blind, Comparator-controlled, Dose-escalation Safety Assessment Study of Combination Treatment with IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients.

Completed
2
50
Europe
IMO-2125, Copegus, Pegasys 180µg, Copegus, Pegasys 180µg
Idera Pharmaceuticals, Inc.
Naïve Hepatitis C
 
01/11
2011-000091-33: 12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who have never before received any treatment for this infection

 
2
25
Europe
IMO-2125, IMO-2125, Copegus, Pegasys 180 μg, Copegus, Pegasys 180 μg
Idera Pharmaceuticals, Inc., Idera Pharmaceuticals Inc.
Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1.
 
01/12
2011-003559-21: Pharmacogenetic analysis study of hepatitis C patients treated with DEB025/Alisporivir alone or with Peg-IFN2a and/or Ribavirin

 
2
140
Europe
Alisporivir, Pagasys, 2221007, Copegus, Pegasys,180 microgramos, solucion inyectable en jeringa precargada
Novartis Pharma Services AG, Novartis Farmaceutica S.A, NOVARTIS FARMA, Novartis Pharma Services AG, Novartis Farmaceutica, Novartis
Hepatitis C and how biomarkers affect the response to treatment of the disease
 
11/12
2016-001010-17: Treatment withdrawal in patients with hepatitis B virus infection to promote clearance of the virus from the body

Ongoing
2
240
Europe
Peginterferon alfa-2a, Solution for injection in pre-filled syringe, Pegasys
Imperial College, London, NIHR EME
Hepatitis B viral infection, Hepatitis B viral infection, Diseases [C] - Virus Diseases [C02]
 
 
 

Download Options